News & Articles

Actionable Insights Tumor Panel enables monitoring of cancer biomarkers from plasma samples

New innovative ZipChip microfluidic inlet technology designed for fast MS analysis of biomolecules

Future joint collaborations are expected as work continues to unlock the full clinical and research potential of both technologies

Reference data set from Horizon affirms proven accuracy of GeneReader workflow

Studies demonstrate pioneering research possible using ChIP technology

Horizon’s X-MAN cell lines to be made available in conjunction with Ubiquigent’s ubiquitin-related Drug Discovery Services

34-gene panel for assessing risk of 15 inherited cancers among new Quest Vantage™ test services to be highlighted during the 2016 ASCO Annual Meeting

Siemens Healthineers will expand its portfolio with molecular testing related services and technologies for oncology and genomics

Direct comparative studies now possible with a set of cancer-specific genes for DNA from tumor tissue or for circulating tumor DNA from liquid biopsy samples

BioTek Instruments, Inc. presented with Scientists' Choice Award® at AACR

Research published online in the International Journal of Cancer, shows the ParsortixTM System efficiently captures and harvests intact, viable circulating tumor cells (CTCs), including EpCAM-negative CTCs, to allow for broader downstream CTC analysis

Agena Bioscience to provide Horizon’s human genomic reference standards to assess quality and performance of oncology-based assays on the MassARRAY System

iPLEX® HS chemistry enables multiplex detection down to 1% allele frequency

New platform enables researchers to rapidly identify cutting-edge anti-cancer drugs

Researchers’ use of ParsortixTM System for studies into multiple cancers confirms the cell separation technology’s ability to harvest viable circulating tumor cells for a broad range of downstream analyses

Agena Bioscience to provide Horizon’s human genomic reference standards to assess quality and performance of oncology-based assays on the MassARRAY System

Visit us at AACR 2016 - Booth 232

In vitro diagnostic approved to support use of Bristol-Myers Squibb’s OPDIVO® for non-squamous non-small cell lung cancer